

Abstract

Identification of a Novel Anti-Mycobacterial Series [†]

Esther Porras * and Carlos Alemparte

GSK, Tres Cantos 28760, Spain; carlos.g.alemparte@gsk.com

* Correspondence: esther.d.porras@gsk.com

[†] Presented at the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain, 8 September 2017.

Published: 20 October 2017

Tuberculosis (TB) is the biggest global killer in history. One of the main objectives for fighting TB is to find a shorter treatment and also to target multidrug-resistant (MDR) and extensively drug-resistant XDR strains. Nowadays, finding and developing new compounds that are active against tuberculosis constitutes a main objective for the Diseases of the Developing World (DDW) center of GlaxoSmithKline (GSK) at Tres Cantos. At our site, both target- and cell-based screens have been approached to identify new anti-TB compounds. *Mtb* phenotypic HTS represents the main source of new chemical entities, although the major challenge resides in their successful optimization and the elucidation of their mechanism of action (MoA).

In this work, we will present a new hit (GSK1) from a whole cell phenotypic screen and also Medicinal Chemistry efforts in the Hit Optimization program to overcome the risks associated with the Lead.

Acknowledgments: We would like to thank Wellcome Trust for the financial support.

Conflicts of Interest: The authors declare no conflicts of interest.



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).